Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 19, 2026Clinical Cancer Research

Abstract PS5-09-06: A Phase II Adjuvant Trial Evaluating the Impact of Omitting Chemotherapy Based on Patient's Selection for Moderate to High-Anatomical Risk, Low-Genomic Risk, ER-positive, HER2-negative Breast Cancer with a Combination Regimen of Ribociclib and Optimized Endocrine Therapy - SELECT Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

JDJ. DuWWWei WeiAKAdriana Kahn

Discussion

Loading...

Member takes

Overview

Phase II trial assesses chemotherapy omission on ribociclib persistence in high-risk breast cancer, suggesting new treatment strategies.

Key Points

  • The study aims to evaluate the impact of omitting chemotherapy on treatment persistence of ribociclib in specific breast cancer patients.
  • Phase II, two-arm, single center, patient preference clinical trial
  • Participants with moderate to high-anatomical risk, low-genomic risk ER-positive, HER2-negative breast cancer
  • Two treatment arms: ribociclib with optimized endocrine therapy vs. chemotherapy followed by ribociclib and optimized endocrine therapy
  • Primary endpoint: one-year discontinuation rate of ribociclib
  • Recruitment ongoing with an estimated 140 participants.
  • Focused on treatment persistence and quality of life.
  • Secondary endpoints include three-year invasive disease-free survival and factors impacting treatment decisions.

Cite This Study

Du et al. (2026) studied this question.

synapsesocial.com/papers/6996a8a9ecb39a600b3ef978https://doi.org/10.1158/1557-3265.sabcs25-ps5-09-06
View Full Paper
Ask AI
Bookmark
Share